TELA · Tela Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.06M | - | $20.69M | $20.20M | $18.52M | - | $18.96M | $16.09M | $16.60M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $12.52M | - | $13.97M | $14.11M | $12.51M | - | $12.86M | $11.07M | $11.34M | - |
| R&D | $2.34M | - | $2.35M | $2.20M | $2.54M | - | $2.07M | $2.32M | $2.39M | - |
| SG&A | $4.17M | - | $3.95M | $4.13M | $3.84M | - | $3.68M | $3.62M | $3.83M | - |
| Total Operating Expenses | $23.05M | - | $21.52M | $23.19M | $22.98M | - | $22.22M | $22.64M | $23.74M | - |
| D&A | $169.0K | - | - | - | $172.0K | - | - | - | $139.0K | - |
| Operating Income | ($10.53M) | - | ($7.55M) | ($9.08M) | ($10.47M) | - | ($9.37M) | ($11.57M) | ($4.83M) | - |
| Interest Expense | $2.05M | - | $1.20M | $1.19M | $1.33M | - | $1.34M | $1.30M | $1.33M | - |
| Income Tax | $60.0K | - | - | $33.0K | $52.0K | - | - | - | - | - |
| Net Income | ($12.27M) | - | ($8.60M) | ($9.92M) | ($11.26M) | - | ($10.37M) | ($12.60M) | ($5.66M) | - |
| EPS - Basic | ($0.21) | - | ($0.19) | ($0.22) | ($0.25) | - | ($0.42) | ($0.51) | ($0.23) | - |
| EPS - Diluted | ($0.21) | - | ($0.19) | ($0.22) | ($0.25) | - | ($0.42) | ($0.51) | ($0.23) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39.54M | $50.84M | $29.71M | $34.98M | $42.83M | $52.67M | $17.30M | $26.50M | $37.14M | $46.73M |
| Accounts Receivable | $9.71M | $10.35M | $11.27M | $11.24M | $10.56M | $10.10M | $11.22M | $9.10M | $9.96M | $9.74M |
| Inventory | $12.21M | $11.02M | $11.56M | $11.37M | $13.53M | $12.78M | $13.60M | $13.37M | $13.60M | $13.16M |
| Accounts Payable | $3.89M | $2.31M | $2.37M | $1.74M | $4.00M | $2.15M | $2.48M | $2.31M | $3.36M | $1.67M |
| Current Assets | $64.30M | $75.58M | $56.05M | $60.74M | $69.75M | $78.07M | $44.13M | $51.11M | $62.62M | $71.73M |
| Total Assets | $69.89M | $81.42M | $61.59M | $67.54M | $77.25M | $86.57M | $53.02M | $60.20M | $71.84M | $78.05M |
| Current Liabilities | $17.83M | $17.98M | $16.98M | $19.06M | $16.54M | $15.60M | $16.86M | $14.99M | $15.18M | $16.97M |
| Long-term Debt | $55.87M | $55.65M | $41.49M | $38.05M | $41.27M | $41.12M | $40.97M | $40.82M | $40.66M | $40.52M |
| Total Liabilities | $75.09M | $75.11M | $60.03M | $58.35M | $59.13M | $58.11M | $59.29M | $57.33M | $57.45M | $59.17M |
| Stockholders' Equity | ($5.20M) | $6.31M | $1.56M | $9.18M | $18.12M | $28.46M | ($6.27M) | $2.87M | $14.38M | $18.88M |
| Retained Earnings | ($409.83M) | ($397.56M) | ($388.52M) | ($379.92M) | ($369.99M) | ($358.73M) | ($349.52M) | ($339.15M) | ($326.55M) | ($320.89M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.17M) | - | - | - | ($9.72M) | - | - | - | ($14.38M) | - |
| Investing Cash Flow | $190.0K | - | - | - | $138.0K | - | - | - | $4.70M | - |
| Financing Cash Flow | ($298.0K) | - | - | - | ($116.0K) | - | - | - | $56.0K | - |
| CapEx | $119.0K | - | - | - | $32.0K | - | - | - | $304.0K | - |
| Free Cash Flow | ($11.29M) | - | - | - | ($9.76M) | - | - | - | ($14.69M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 65.7% | - | 67.5% | 69.8% | 67.6% | - | 67.8% | 68.8% | 68.3% | - |
| Operating margin | -55.2% | - | -36.5% | -45.0% | -56.5% | - | -49.4% | -71.9% | -29.1% | - |
| EBITDA margin | -54.3% | - | - | - | -55.6% | - | - | - | -28.2% | - |
| Net margin | -64.4% | - | -41.6% | -49.1% | -60.8% | - | -54.7% | -78.3% | -34.1% | - |
| Free cash flow margin | -59.2% | - | - | - | -52.7% | - | - | - | -88.5% | - |
| FCF / Net income | 0.92 | - | - | - | 0.87 | - | - | - | 2.59 | - |
| R&D / Revenue | 12.3% | - | 11.3% | 10.9% | 13.7% | - | 10.9% | 14.4% | 14.4% | - |
| SG&A / Revenue | 21.9% | - | 19.1% | 20.4% | 20.7% | - | 19.4% | 22.5% | 23.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -17.6% | - | -14.0% | -14.7% | -14.6% | - | -19.6% | -20.9% | -7.9% | - |
| Return on equity | 236.0% | - | -552.5% | -108.0% | -62.2% | - | 165.4% | -439.0% | -39.4% | - |
| Return on invested capital | -16.4% | - | - | -15.2% | -13.9% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.61 | 4.20 | 3.30 | 3.19 | 4.22 | 5.01 | 2.62 | 3.41 | 4.13 | 4.23 |
| Quick ratio | 2.92 | 3.59 | 2.62 | 2.59 | 3.40 | 4.19 | 1.81 | 2.52 | 3.23 | 3.45 |
| Cash ratio | 2.22 | 2.83 | 1.75 | 1.84 | 2.59 | 3.38 | 1.03 | 1.77 | 2.45 | 2.75 |
| Leverage | ||||||||||
| Debt / Equity | -10.74 | 8.82 | 26.65 | 4.14 | 2.28 | 1.45 | -6.53 | 14.22 | 2.83 | 2.15 |
| Debt / Assets | 0.80 | 0.68 | 0.67 | 0.56 | 0.53 | 0.48 | 0.77 | 0.68 | 0.57 | 0.52 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.1x | - | -6.3x | -7.6x | -7.9x | - | -7.0x | -8.9x | -3.6x | - |
| Equity multiplier | -13.44 | 12.90 | 39.55 | 7.35 | 4.26 | 3.04 | -8.45 | 20.98 | 4.99 | 4.13 |
| Liabilities / Assets | 1.07 | 0.92 | 0.97 | 0.86 | 0.77 | 0.67 | 1.12 | 0.95 | 0.80 | 0.76 |
| Efficiency | ||||||||||
| Asset turnover | 0.27 | - | 0.34 | 0.30 | 0.24 | - | 0.36 | 0.27 | 0.23 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 186d | - | 199d | 203d | 208d | - | 216d | 206d | 219d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 43.5x | 9.6x | 3.0x | - | - | 40.4x | 9.7x | - |
| P / S | 1.9x | - | 3.3x | 4.4x | 3.0x | - | 3.3x | 7.2x | 8.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 2.9% | - | 9.1% | 25.5% | 11.5% | - | 25.9% | 11.0% | 39.4% | - |
| Revenue CAGR (3y) | 17.0% | - | 22.8% | 24.7% | 31.0% | - | 35.3% | 28.6% | 41.4% | - |
| Revenue CAGR (5y) | 26.5% | - | 31.2% | 43.6% | 37.8% | - | 53.7% | - | - | - |
| Gross profit growth (YoY) | 0.1% | - | 8.6% | 27.4% | 10.4% | - | 23.8% | 8.5% | 43.5% | - |
| Operating income growth (YoY) | -0.5% | - | 19.3% | 21.5% | -117.0% | - | 8.0% | -11.7% | 57.1% | - |
| Net income growth (YoY) | -9.0% | - | 17.1% | 21.2% | -99.0% | - | 5.3% | -16.8% | 52.9% | - |
| EPS growth (YoY) | 16.0% | - | 54.8% | 56.9% | -8.7% | - | 6.7% | -10.9% | 63.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -15.7% | - | - | - | 33.6% | - | - | - | -25.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -77.8% | - | 220.0% | 26.0% | 50.7% | - | -92.8% | 357.9% | 32.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$80.28M totalSingle Reportable Segment$80.28M · 100.0%
Geographic
$12.10M totalNon Us$12.10M · 100.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing TELA Bio against the 5 most active filers in the same SIC group.